WO2017040671A1 - Systèmes et procédés d'histo-tomographie de fluorescence (fht) - Google Patents

Systèmes et procédés d'histo-tomographie de fluorescence (fht) Download PDF

Info

Publication number
WO2017040671A1
WO2017040671A1 PCT/US2016/049708 US2016049708W WO2017040671A1 WO 2017040671 A1 WO2017040671 A1 WO 2017040671A1 US 2016049708 W US2016049708 W US 2016049708W WO 2017040671 A1 WO2017040671 A1 WO 2017040671A1
Authority
WO
WIPO (PCT)
Prior art keywords
fluorescence
white light
fht
chamber
image
Prior art date
Application number
PCT/US2016/049708
Other languages
English (en)
Inventor
John W. HOPPIN
John V. Frangioni
Robert William HOLT
Mohammed Q. QUTAISH
Marc Edward SEAMAN
Mark W. BORDO
Jacob Yost HESTERMAN
Original Assignee
Invicro, Llc
Curadel, LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US15/158,928 external-priority patent/US9799113B2/en
Application filed by Invicro, Llc, Curadel, LLC filed Critical Invicro, Llc
Priority to KR1020187002483A priority Critical patent/KR20180048586A/ko
Priority to AU2016315795A priority patent/AU2016315795C1/en
Priority to EP16842910.8A priority patent/EP3298383A4/fr
Priority to CA2987919A priority patent/CA2987919A1/fr
Priority to JP2018530666A priority patent/JP6719123B2/ja
Publication of WO2017040671A1 publication Critical patent/WO2017040671A1/fr

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N21/00—Investigating or analysing materials by the use of optical means, i.e. using sub-millimetre waves, infrared, visible or ultraviolet light
    • G01N21/62—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light
    • G01N21/63—Systems in which the material investigated is excited whereby it emits light or causes a change in wavelength of the incident light optically excited
    • G01N21/64—Fluorescence; Phosphorescence
    • G01N21/645—Specially adapted constructive features of fluorimeters
    • G01N21/6456—Spatial resolved fluorescence measurements; Imaging
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N1/00—Sampling; Preparing specimens for investigation
    • G01N1/02—Devices for withdrawing samples
    • G01N1/04—Devices for withdrawing samples in the solid state, e.g. by cutting
    • G01N1/06—Devices for withdrawing samples in the solid state, e.g. by cutting providing a thin slice, e.g. microtome

Definitions

  • FHT FLUORESCENCE HISTO-TOMOGRAPHY
  • the present disclosure relates generally to imaging and, more specifically, to fluorescence histo-tomography (FHT) systems and methods.
  • FHT fluorescence histo-tomography
  • Multispectral fluorescence tissue slice imaging can be used to measure drug distribution ex-vivo in standalone or retrofitted slice imagers. Such specificity in a single imaging system can result in a high cost per scan. For high throughput and low cost, it would be valuable to construct a fluorescence histological (histo-) imager with a corresponding software package that can work in tandem with slicing instruments. To that end, the methods outlined here demonstrate a workflow of fluorescence imaging techniques for a versatile, transportable add-on to existing histological slicing instruments.
  • a fluorescence histo-tomography (FHT) system includes a housing, a fluorescence camera located within the housing, a white light camera located within the housing, and a fluorescence light source located within the housing.
  • the FHT system further includes a support mount configured to support the housing within a chamber of a slicing apparatus such that the cameras and fluorescence light source are aimed towards a block face of a tissue specimen retained within the chamber.
  • a method for performing FHT includes capturing, by an imaging device mounted within a chamber of a slicing apparatus, a white light image of a block face of a tissue specimen retained within the chamber.
  • the method also includes capturing, by the imaging device, a fluorescence image of the block face under white light and fluorescence illumination.
  • the method further includes co-registering, by the imaging device, the white light and fluorescence images to form a combined image.
  • the method additionally includes providing, by the imaging device, the combined image to an electronic display.
  • a FHT system in additional embodiments, includes means for imaging a block face of a tissue specimen retained within a chamber of a slicing apparatus.
  • the FHT system also includes means for supporting the imaging means within the chamber of the slicing apparatus.
  • FIGS. 1A-1B illustrate an example cryostat/cryomicrotome, according to various embodiments.
  • FIGS. 2-4 illustrate an example fluorescence histo-tomography (FHT) imaging device for use in a microtome or cryomicrotome, according to various embodiments.
  • FHT fluorescence histo-tomography
  • FIG. 5 illustrates an example computing device of a FHT system, according to various embodiments.
  • FIG. 6 illustrates an example simplified procedure for preparing a tissue specimen for FHT imaging, according to various embodiments.
  • FIG. 7 illustrates an example simplified procedure for imaging a block face of a tissue specimen using FHT imaging, according to various embodiments.
  • FIG. 8 illustrates an example registration scheme for images captured by a FHT system, according to various embodiments.
  • FIGS. 9A-9I illustrate test results of FHT imaging of a fluorophore-infused piece of twine, according to various embodiments.
  • FIGS. 10A-10B illustrate test results of FHT imaging of brain tissue, according to various embodiments.
  • FIGS. 1 lA-1 IF illustrate further test results of FHT imaging of brain tissue, according to various embodiments.
  • FIGS. 12A-12I illustrate additional examples of FHT imaging of brain tissue, according to various embodiments.
  • FIG. 13A-13E illustrate examples of the imaging of intrathecally-administered anti-sense oligonucleotides, according to various embodiments.
  • FIGS. 14A-14C illustrate examples of a mechanism to remove stuck tissues slices from an FHT system.
  • FIGS. 15A-15B illustrate an example apparatus for precisely placing fiducial markers in a tissue block.
  • FIG. 16 illustrates an example of multi-colored fiducial markers.
  • NIR fluorescent light has the ability to provide high contrast in the context of normal bodily tissues and fluids.
  • the techniques described herein utilize simultaneous color/NIR acquisition to acquire data sets and mathematical methods applied to these data sets to reconstruct in ultra-high resolution, at least an approximation of the actual NIR fluorescence present in the tissue block and therefore the original living tissue.
  • NIR also provides high sensitivity and less interference from endogenous chromophores that would otherwise preclude visible fluorescence imaging.
  • FIG. 1A a cryostat/cryomicrotome 100 is shown, according to various embodiments.
  • a microtome is a device typically used to prepare histologic samples of a tissue block for use in microscopy.
  • a microtome may shave a thin layer of a tissue specimen from a tissue block that can then be mounted to a slide for observation using a microscope.
  • a cryomicrotome is a specialized form of microtome operable to keep the tissue specimen at a reduced temperature during slicing. While the FHT system disclosed herein is described with respect to a cryomicrotome, the teachings herein are not limited as such. In particular, the FHT system can be implemented using any number of different slicing devices (e.g., other microtomes, histological sample preparation devices, macrotomes, etc.).
  • cryomicrotome 100 may include a housing 102 that encompasses a sealed chamber 106 in which the cutting operation is performed. Cryomicrotome 100 may also include a door 104 or other access mechanism (e.g., lid, etc.) that afford the user of cryomicrotome 100 access to chamber 106. During use, cryomicrotome 100 may regulate the internal temperature of chamber 106 to prevent a frozen tissue specimen being sliced from thawing back to room temperature.
  • a door 104 or other access mechanism e.g., lid, etc.
  • FIG. IB illustrates an example chamber 106 of cryomicrotome 100 in greater detail.
  • cryomicrotome 100 may include a specimen retainer 110 that holds a frozen specimen 112 in place.
  • cryomicrotome 100 may also include one or more cutting blades 108 that, when actuated, moves across the block face of specimen 112 to remove a thin layer of specimen 112.
  • specimen 112 may be any form of biological material extricated from a subject and may be frozen in an optimal cutting temperature (OCT) material, prior to placement in cryomicrotome 100.
  • OCT optimal cutting temperature
  • the alignment of cutting blade 108 and specimen retainer 110 may be configurable in some cryomicrotomes to adjust, e.g., the thickness of the resulting tissue slice and/or to ensure proper contact of cutting blade 108 with tissue specimen 112.
  • a user of cryomicrotome 100 may first ensure the correct positions of tissue specimen 112 before initiating slicing of the tissue specimen 112.
  • actuation of cutting blade 108 may be performed manually by the user.
  • actuation of cutting blade 108 and/or movement of specimen retainer 110 may be performed automatically by cryomicrotome 100 under computerized control.
  • cryomicrotome that can be used to implement the techniques herein is the Leica 3050 cryomicrotome available from Leica Camera AG, Wetzlar, Germany.
  • the techniques herein can be applied to any number of different cryomicrotomes and are not limited to a particular make, model, or type of cryomicrotome.
  • the fluorophores that can be used for purposes of fluorescence imaging may exhibit emission spectra in the range of approximately 200 nm to 1000 nm. Further, a plurality of fluorophores can be used on a single specimen if each of the used fluorophores has different emission spectra. Other fluorophores not listed in Table 1 can also be used without deviating from the teachings herein.
  • NIR fluorescence imaging can be leveraged with a cryomicrotome to perform fluorescence histo-tomography (FHT) of a tissue specimen.
  • cryomicrotomes are typically used to prepare tissue slices for further analysis (e.g., by mounting a slice to a microscope slide, etc.).
  • the FHT techniques herein propose the exact opposite, i.e., by imaging the exposed block face of the tissue specimen itself while in the cryomicrotome without any regard to the resultant tissue slices, which may be discarded or retained as desired by the user.
  • the FHT system may include an imaging
  • Imaging system 200 may be transportable, allowing imaging system 200 to be used with any number of different types of cryomicrotomes.
  • this allows a user to adapt a cryomicrotome to perform FHT imaging without having to make significant modifications to the cryomicrotome.
  • Imaging system 200 may include a housing 202 that houses the various imaging components of system 200.
  • housing 202 may include a handle 204 that allows the user to position housing 202 within chamber 106 of cryomicrotome 100 and/or remove imaging system 200 therefrom, as desired.
  • Housing 202 may be formed of any suitable materials such as plastics, ceramics, or sheet metal and may protect the imaging components of imaging system 200 from the internal climate of chamber 106 of cryomicrotome 100 (e.g., to protect a camera from exposure to the colder temperatures, etc.). At least a portion of housing 202 may also be at least semi-transparent such that light in the white and NIR spectrums may pass through housing 202. Further, while housing 202 is shown with a primarily cylindrical shape, other implementations of housing 202 may take on other geometric shapes, e.g., to fit within the chambers of certain types or models of cryomicrotomes.
  • the FHT system may also include one or more support brackets or other retaining members, to position the imaging components in housing 202 at a suitable distance within chamber 106 of cryomicrotome 100 relative to tissue specimen 112.
  • support mount/bracket 210 may contact the floor of chamber 106 and support housing 202 at a distance therefrom.
  • housing 202 may be positioned at any desired distance from the block face of tissue specimen 112, testing has shown that a distance of approximately ten inches yields suitable FHT imaging results of the sample while not impinging the motion of cutting blade 108, as shown in greater detail in FIG. 3.
  • bracket 210 may be coupled or otherwise fastened to the floor of chamber 106 (e.g., via one or more screws, bolts, etc.). In other embodiments, bracket 210 may be shaped to engage one or more components of cryomicrotome 100 (e.g., to slide under the structure associated with cutting blade 108, etc.). In addition, bracket 210 may be a separate component from that of housing 202 (e.g., housing 202 rests on bracket 210), may be fastened or coupled thereto, or may be directly formed as part of housing 202, according to various embodiments.
  • the imaging components of imaging system 200 may include one or more cameras, such as one or more charge-coupled device (CCD) camera(s) 206 and one or more illumination light sources/fibers 208.
  • CCD charge-coupled device
  • camera(s) 206 may include a white light camera configured to capture images within the visible spectrum and/or a fluorescence camera configured to capture images in the NIR or IR spectrum.
  • illumination light sources/fibers 208 may include one or more fibers to shine fluorescent and/or white light onto the block face of tissue specimen 112 during imaging. Extending out of the back of housing 202 may be cabling 212 that connect camera(s) 206 and illumination sources/fibers 208 to a computing device 300, as shown in FIG. 4.
  • imaging system 200 may further include one or more white light sources as part of imaging system 200, such as part of illumination fibers 208 or lights located on the end of housing 202, or external to housing 202 (e.g., a surgical lamp, a camera flash, etc.).
  • white light sources as part of imaging system 200, such as part of illumination fibers 208 or lights located on the end of housing 202, or external to housing 202 (e.g., a surgical lamp, a camera flash, etc.).
  • Camera(s) 206 may be of any suitable type operable to capture images in the white light and NIR spectrums.
  • one prototype of the FHT system herein uses a high resolution Canon EOS 700 white light camera available from Canon, Melville, NY, although any other suitable white light camera can be used in other implementations.
  • suitable systems include the K-FLARE ® , and Lab-FLARE® models RlTM, RlvTM, RP1TM, RP2TM, RC2TM, FLARE® (FLuorescence-Assisted Resection and Exploration) imaging systems available from Curadel LLC, Marlboro, MA.
  • Other suitable system components may be used, as desired, without deviating from the teachings herein.
  • imaging system 200 may include polarizers with camera(s) 206 and/or the illumination sources (e.g., illumination fibers 208).
  • imaging system 200 may use concentric linear polarizers with excitation and emission rotated at 90 degrees, which will reduce specular reflections from the illuminated tissue specimen 112.
  • FIG. 5 illustrates an example schematic block diagram of computing device 300, according to various embodiments.
  • computing device 300 may comprise one or more interfaces 310 (e.g., wired, wireless, etc.), at least one processor 320, and a memory 340 interconnected by a system bus 350 and powered by a power supply 360.
  • Interface(s) 310 contain the mechanical, electrical, and signaling circuitry for communicating data with other computing devices in the FHT system.
  • interfaces 310 may be communicatively coupled to camera(s) 206 and illumination fibers 208 of imaging system 200 via cabling 212 either directly or via any number of intermediate components.
  • interface(s) 310 may be in communication with one or more light sources for illumination fibers 208, to provide control over when the light sources are activated (e.g., to shine fluorescent light on tissue specimen 112).
  • interface(s) 310 may receive captured image data from the white light and fluorescence cameras of imaging system 200 for further image processing.
  • interface(s) 310 may also be in communication with one or more user interface devices.
  • a user interface device provides sensory information to a user and/or receives input from the user via one or more sensors.
  • user interface devices may include, but are not limited to, electronic displays (e.g., to display the resulting images of the tissue block face to the user), pointing devices (e.g., track pads, touch screens, etc.), audio equipment (e.g., speakers, microphones, etc.), and the like.
  • interface(s) may also communicatively couple computing device 300 to other computing devices via a hardwired or wireless network (e.g., to convey image data to another device, to receive instructions from another device, etc.).
  • the memory 340 comprises a plurality of storage locations that are addressable by the processor 320 and interface(s) 310 for storing software programs and data structures associated with the embodiments described herein.
  • the processor 320 may comprise hardware elements or hardware logic adapted to execute the software programs and manipulate the data structures 345, which may include received sensor data (e.g., captured image data, etc.), operating parameters or settings, and the like.
  • These software processes and/or services may comprise, in various embodiments, an illumination controller process 347 and/or an imaging process 248, as described herein.
  • processor and memory types including various computer-readable media, may be used to store and execute program instructions pertaining to the techniques described herein.
  • description illustrates various processes, it is expressly contemplated that various processes may be embodied as modules configured to operate in accordance with the techniques herein (e.g., according to the functionality of a similar process). Further, while the processes have been shown separately, those skilled in the art will appreciate that processes may be routines or modules within other processes.
  • illumination controller 347 may be configured to control when the fluorescent light source, and possibly the white light source, is activated.
  • the light source itself, such as a light emitting diode (LED), laser, etc., may be in communication with computing device 300 and may be optically coupled to illumination fibers 208, to emit the corresponding light onto the block face of tissue specimen 112.
  • illumination controller 347 may control when imaging system 200 illuminates tissue specimen 112 with NIR or IR wavelengths, to provoke an excitation response from the fluorophore(s) present within the tissue.
  • Imaging process 248 may be operable to acquire and/or process images captured by imaging system 200.
  • imaging process 248 may send control signals to camera(s) 206 to capture white light and/or fluorescence images of the block face of tissue specimen 112.
  • imaging process 248 may receive the captured image data from camera(s) 206 and perform image processing, as described below, to generate a finalized image for output to an electronic display.
  • imaging process 348 may be further configured to control one or more automated functions of cryo microtome 100, such as automated actuation of cutting blade 108, movement of specimen retainer 110, etc.
  • procedure 600 is shown for preparing a tissue specimen for FHT image acquisition, according to various embodiments. As shown, procedure 600 may start at step 605 and continue on to step 610 at which the subject
  • this step may entail selecting a suitable fluorophore for the tissue specimen and injecting the selected fluorophore(s) into the specimen. For example, as shown previously in Table 1, different fluorophores may have different spectral properties and applications.
  • the soft tissue for analysis may be excised.
  • the subject may be embedded in a block of OCT compound. Any suitable OCT compound may be selected for this step.
  • the OCT-encased subject tissue block may then be installed into position within the cryomicrotome (e.g., as shown in FIG. IB).
  • Procedure 600 may also include a step 620 in which the FHT imaging system
  • imaging system 200 may be positioned in front of the specimen block face of tissue specimen 112 within chamber 106 of cryomicrotome 100 for imaging of the block face, as described above.
  • the fluorescence components may be positioned such that as much of the subject specimen as possible is in focus for the camera and the subject subtends the largest possible field of view without occlusion.
  • Procedure 600 may also include a step 625 at which a fluorescence channel is selected for the imaging system.
  • a fluorescence channel is selected for the imaging system.
  • different NIR channels may be selected, based on the fluorophore used on the tissue specimen in step 610. If multiple fluorophores are used on the specimen, the corresponding NIR channels may be selected to overlap the spectral properties of the
  • procedure 600 may include a step 630 at which a high resolution white light camera is pointed at the tissue specimen. If, for example, the white light camera and fluorescence camera are both located within the same housing (e.g., housing 202), steps 620 and 630 may be performed at the same time by positioning the housing within the chamber of the cryomicrotome relative to the tissue specimen.
  • the user may adjust the positions of the fluorescence and white light cameras, as needed. For example, based on test images acquired by the cameras, the positions of the cameras may be further adjusted to ensure that the desired area of the block face of the tissue is captured, the cameras are in focus, or for any other reason.
  • step 640 of procedure 600 once the white light and fluorescence imaging systems are positioned at a desirable location relative to the block face of the OCT block, the components may be locked into position. For example, if the imaging components are housed within a single housing, the position of the housing within the chamber of the cryomicrotome may be solidified, once the desired position is achieved.
  • the blade(s) of the cryomicrotome may be actuated to shave the OCT block until the tissue is nearly exposed.
  • the exposed block face may comprise only a very fine layer of OCT compound in front of the encased tissue for imaging.
  • Procedure 600 then ends at step 650.
  • procedure 700 may be performed in whole, or in part, by operating a FHT system having a computing device (e.g., device 300) in communication with an imaging system (e.g., imaging system 200).
  • a computing device e.g., device 300
  • an imaging system e.g., imaging system 200
  • Procedure 700 may start at step 705 and continue on to step 710 where, as described in greater detail above, the room lights may be activated in the room in which the FHT system is located. Depending on the capabilities of the imaging system, ambient light from the room lights may provide sufficient white light for purposes of imaging.
  • the FHT system may acquire an image of the block face of the tissue specimen using its white light camera.
  • the computing device of the FHT system may signal the white light camera to capture a high definition, white light image of the block face of the tissue specimen within the chamber of the cryomicrotome.
  • the FHT system may also capture one or more images using its fluorescence imaging components simultaneously with the step 715 or within a short time before or thereafter.
  • the fluorescence imaging components may capture both white light and fluorescence/NIR images of the block face of the tissue specimen.
  • the fluorescence camera may capture images of the block face with the room lights activated, with and without fluorescence illumination, as well.
  • the room lights may be disabled to remove the white light source from the tissue specimen.
  • steps 710 and 725 may entail turning the white light source on and off, as needed.
  • the FHT system may also capture an image of the block face under fluorescence illumination with the room lights deactivated.
  • the FHT system may have any or all of the following distinct images of the block face: 1.) a white light image captured by the white light camera while the block face was illuminated with white light (e.g., with the room lights on), 2.) a fluorescence image captured by the fluorescence imaging system while the block face was illuminated solely with white light, 3.) a fluorescence image captured by the fluorescence imaging system while the room lights and fluorescent light sources were both on, 4.) a fluorescence image captured by the fluorescence imaging system while all light sources were off, and 5.) a fluorescence image captured by the fluorescence imaging system while the white light source was off and the fluorescent lighting source was turned on.
  • the room lights may be reactivated, after completing the imaging of the block face.
  • the blade(s) of the cryomicrotome may be activated to cut the OCT block, thereby exposing another portion of the sample for imaging.
  • any breaks in the protocol defined by the steps above may be noted at a step 745. For example, if a superfluous image was taken, a note may be may and associated with any of the images captured of the exposed block face, thereby allowing these images to be discarded or otherwise ignored.
  • procedure 700 a decision may be made as to whether the removed layer of tissue from the OCT block is the last layer of interest. If not, procedure 700 may return to step 715, thereby repeating steps 715-745 for the newly exposed layer. However, if the final layer of tissue has been imaged, procedure 700 may continue on to step 755 where procedure 700 then ends.
  • procedures 600-700 may be optional as described above, the steps shown in FIGS. 6-7 are merely examples for illustration, and certain other steps may be included or excluded as desired. Further, while a particular order of the steps is shown, this ordering is merely illustrative, and any suitable arrangement of the steps may be utilized without departing from the scope of the embodiments herein. Moreover, while procedures 600-700 are described separately, certain steps from each procedure may be incorporated into each other procedure, and the procedures are not meant to be mutually exclusive.
  • an illustration 800 is shown of the registration of images within a FHT system, according to various embodiments.
  • the FHT computing device e.g., device 300 executing imaging process 248, may co-register the various captured images (e.g., images captured via procedure 700 shown in FIG. 7), to generate the finalized image(s).
  • the finalized images may then be provided to an electronic display or another user interface device, for review by a human user.
  • the following labels are assigned to their
  • WL FLARE ON the image 805 captured in the white light channel of the fluorescence imaging system of the block face illuminated with white light.
  • WL FLARE OFF the image captured in the white light channel of the fluorescence imaging system of the block face with all white lights off but fluorescence excitation light on.
  • FL FLARE ON the image 815 captured in the fluorescence channel of the fluorescence imaging system with the block face illuminated with both fluorescence excitation and white light.
  • the computing device may perform image processing by performing any or all of the following, as shown in FIG. 8:
  • the computing device may perform co-registration on a per-image basis, with the exception of the WL_HIGH_ON images.
  • the above procedures are exemplary only and are not intended to limit the teachings herein.
  • the above procedures may be of particular use in cases where the output of the fluorescent light source is comparable to the white light source (e.g., stray room lighting, etc.).
  • the above techniques may be modified to allow for single- slice white light and fluorescence images to be captured simultaneously with the room lights on and natively co-registered to each other.
  • optical filters may be used on the fluorescence image in such cases, thereby simplifying the image captures under different lighting conditions.
  • the imaging components may instead comprise the LAB -FLARE® imaging system from Curadel, LLC or a similar system. Such systems may allow for the simultaneous acquisition of different images (e.g., color and NIR, etc.), thereby eliminating the need to switch off and on the white light source (e.g., the room lights).
  • FIGS. 9A-9I illustrate test results of FHT imaging of a fluorophore-infused piece of twine, according to various embodiments.
  • imaging of a piece of twine comprising a plurality of individual strands was performed as a proof-of-concept using a prototype FHT system employing the techniques herein. During testing, the following steps were performed:
  • the wrapped pillow was embedded in a larger OCT block and frozen for slicing by the FHT system.
  • the camera sub-system was positioned approximately 15 cm above the block, resulting in a field of view (FOV) of ⁇ 5 x 5 cm and a transverse pixel size of -0.085 mm.
  • FOV field of view
  • FIGS. 9A-9B illustrate the original captured images 900-910 of the twine using the FHT system. As shown, images 900-910 demonstrate a contrast between the portions of the twine that have high concentrations of the fluorophore and the portions of the twine that do not.
  • the FHT system may further employ subtraction- based deblurring, to produce an image for display.
  • FIGS. 9C-9D illustrate images 900-910, respectively, after performing subtraction-based deblurring.
  • the deblumng may also involve running a Monte Carlo simulation, using a point spread function method, or performing a deconvolution method.
  • the deconvolution method may include one of a measured point spread function kernel, a simulated point spread function kernel, a Richardson- Lucy method, a Weiner filter deconvolution, a Van Cittert deconvolution, a blind deconvolution, or a regularized deconvolution method.
  • FIGS. 9E-9F illustrate further images 930-940 of the twine in both original and deblurred forms, respectively.
  • FIGS. 9G-9I also depict images 950-970 of area 942 of image 940, to illustrate the application of different image processing techniques to the images.
  • image 950 illustrates area 942 in its original form from the fluorescence imaging system.
  • Image 960 in FIG. 9H then illustrates image 950 after performing subtraction-based deblurring.
  • the FHT system may further apply edge-preserving smoothing to image 960, resulting in image 970 shown in FIG. 91.
  • Ex vivo imaging methodologies such as immunohistochemistry, fluorescence imaging, and autoradiography have been used to study anatomy, physiology and drug or tracer distribution in either whole bodies or excised organs. These methodologies can follow and accompany in vivo imaging studies or serve as stand-alone studies themselves. Because ex vivo processing is relatively expensive and time consuming, often sections and/or images are taken at large intervals (0.1-1 mm) throughout the entire specimen. Information is lost in these gaps where sections are not collected or imaged. Further, if a three dimensional model of the specimen is required, interpolation of largely spaced sections is required and the model may suffer.
  • high resolution white light and multispectral (700 and 800 nm) fluorescence images may be captured off the block after every pass of the micro- or macrotome blade using an intraoperative fluorescence imaging system, thus vastly improving the amount of information captured throughout the specimen and decreasing total acquisition time.
  • cryofluorescence tomography FHT.
  • organs or small animal whole bodies may be sectioned (e.g., at 25 microns, etc.) and all images may be captured and acquired in less than 2 hours, improving some shortcomings of various ex vivo techniques, while enabling the creation of high resolution 3D models.
  • the animal was sacrificed, the brain tissue excised, and the sample was
  • a fluorescent zwitterionic compound ZW800-1 (Curadel, LLC) was injected into the rat intrathecal space. This compound is not expected to cross into the brain parenchyma due to its chemical properties. As shown, ZW800-1 signal is constrained in the ventricles and subarachnoid space, while it is noticeably absent in brain parenchyma.
  • ZW800-1 signal is constrained in the ventricles and subarachnoid space, while it is noticeably absent in brain parenchyma.
  • FIGS. 10A-12I Various images captured during testing are shown in FIGS. 10A-12I.
  • FIG. 10A-10B depict images 1000 and 1010 of the brain tissue with the white light captures colored gray and the fluorescence images colored orange/purple.
  • FIG. 11 A illustrates FHT images 1100 using maximum intensity projection (MIP).
  • FIGS. 11 lB-11 ID illustrate sagittal, coronal, and transverse dual camera static images 1110-1130, respectively (e.g., images 1110-1130 are combined images of the white light and fluorescence captures).
  • FIG. 1 lE-1 IF illustrate dual camera, MIP images 1140-1150, respectively.
  • FIGS. 12A-12C illustrate white light images 1200-1220 of the coronal, axial, and saggital planes, respectively.
  • FIGS. 12D-12F illustrate fluorescent images 1230-1250 of the 2-DG taken up in the brain parenchyma along the coronal, axial, and saggital planes respectively.
  • images 1260-1280 depict the fluorophore, ZW800-1 constrained in the ventricles and
  • FHT serves as a multispectral, high resolution, and time efficient ex vivo tool to study anatomy, physiology, and drug/tracer distribution, either in concert with in vivo studies or as a stand-alone study.
  • Antisense oligonucleotides are promising drugs for treating central nervous system (CNS) disorders due to their specific targeting and extended pharmacological effect.
  • CNS central nervous system
  • the development of therapeutics for CNS disorders has been impeded by the inability of most drug molecules to cross the blood brain barrier (BBB) and engage their targets.
  • BBB blood brain barrier
  • IT intrathecal
  • PK pharmacokinetics
  • PD pharmacodynamics
  • imaging approaches are disclosed herein using radio and fluorophore- labeled ASOs tracking PK. Further aspects of the techniques herein employ neuroreceptor targeting ASOs to enable tracking of PD using receptor-targeting radiotracers. During testing, these PK/PD principles were evaluated using two ASOs which target the MALAT1 house keeping gene and the GABA-A receptor subunit GABRAl. Dynamic SPECT/CT imaging with the 125I-MALAT1 ASO showed widespread time and dose dependent exposure of the neuroaxis tissues following lumbar IT injections, with increased exposure in cortical structures versus basal ganglia.
  • a 3D-FHT imaging technique was developed to demonstrate the correlation between the distributions of the IT administered Cy7-labeled GABRAl ASO with the regional receptor knockdown demonstrated in the 18F-flumazenil.
  • This 3D cryofluorescence imaging technique offers a bridge between in vivo molecular imaging and ex vivo histology enabling the 3D visualization of the PK/PD relationship for ASO therapy.
  • ASO anti-sense oligonucleotide
  • the rats underwent 1 hour dynamic 18 F-flumazenil PET scans at baseline (day prior to ASO treatment), then at 1, 2, 3, 4 weeks post treatment. Phamacodynamics of treatment is followed by 18 F-flumazenil PET, pharmacokinetics and distribution demonstrated by Cy7-labeled GABRA1 ASO.
  • Image 1300 in FIG. 13 A illustrates averaged MIP, sagittal, coronal and transverse 18 F- flumazenil PET area under the curve (AUC) images for MALATl and GABRA A ASO-treated groups at 4 weeks post single-dose treatment. Images were co-registered to a common atlas space and scaled to units of decay-corrected uCi-min. Note the decreased 18 F-flumazenil uptake post GABRA A versus MALATl ASO treatment.
  • FIG. 13C illustrates a graph 1320 of the 18 F-flumazenil PET (AUC axis 1324) for volume of interest on cerebral cortex at baseline and at 1, 2, 3 and 4 weeks post single dose ASO treatment (time axis 1322). The cortex uptake showed significant reduction in GABRA A versus MALATl targeted treatment a 2, 3, and 4 weeks.
  • FIG. 13D depicts an image 1330 of the MIP sagittal, coronal and transverse 3D-FHT images of IT administered Cy7-labeled GABRA1 ASO at 1 hour post administration.
  • FIG. 13E shows an image 1340 of the MIP sagittal, coronal and transverse 3D-FHT images of IT administered Cy7-labeled GABRA1 ASO at 4 days post administration. Clearing Tissue Slices
  • the cut tissue slice may "stick" to the remaining tissue block after slicing, either due to electrostatic, hydrophobic, or other interactions between the slice and the block.
  • the FHT system may further include a mechanism that blows a puff of gas, such as air, or a non-humidity- containing gas such as nitrogen, onto the block face at the end of a slicing cycle to remove any tissue that might otherwise stick to the block and obscure imaging.
  • the mechanism may generally include a gas cylinder 1402 that stores a gas such as air, nitrogen, or argon.
  • a gas such as air, nitrogen, or argon.
  • any form of gas may be selected as desired, depending on the type of tissue specimen, environmental conditions, etc.
  • water vapor i.e., humidity
  • gasses such as nitrogen and argon may be preferable.
  • gas cylinder 1402 may be pneumatically coupled to the FHT system via a tubing system 1404 and a control mechanism 1406, as shown in FIG. 14A.
  • control mechanism 1406 may be configured to regulate the flow of gas from gas cylinder 1402 through tubing system 1404 and onto the face of the tissue block, to dislodge stuck tissue slices. In other words, control mechanism may adjust the force of the gas puff so that the gas will reliably dislodge the tissue slice completely from the block.
  • tubing system 1404 may convey the gas from gas cylinder 1402 onto the tissue block face via control mechanism 1406.
  • control mechanism 1406 may include a pressure regulator 1408, a solenoid valve 1410, and control electronics 1412, in various embodiments.
  • pressure regulator 1408 controls the amount of gas pressure in tubing system 1404, allowing the user to adjust the pressure such that any stuck tissue slices are dislodged by the gas exiting the nozzle of tubing system 1404.
  • Solenoid valve 1410 may also be coupled to tubing system 1404 and control the flow of gas through tubing system 1404. For example, when actuated, solenoid valve 1410 may block or unblock the flow of gas through tubing system 1404 so as to provide a puff of gas onto the block face of the tissue specimen.
  • control electronics 1412 may provide electronic or computerized control over solenoid valve 1410 and/or pressure regulator 1408, to control when the system supplies a puff of gas and/or the pressure of the supplied gas. Such electronics 1412 may either fully automate the actuation of the system or may allow a user to manually trigger the puff of gas.
  • FIG. 14C shows tubing system 1404 in greater detail, according to various embodiments.
  • tubing system 1404 may include tubing 1414 that couples a nozzle 1416 to gas cylinder 1402 via control mechanism 1406.
  • nozzle 1416 may be located at a suitable distance from the block face of the tissue specimen and may, in some embodiments, be coupled to the slicing apparatus (e.g., a microtome, etc.), to ensure that nozzle 1416 remains pointed towards the tissue specimen after each puff of gas.
  • the slicing apparatus e.g., a microtome, etc.
  • tubing 1414 and nozzle 1416 may be located within the temperature-controlled chamber of the cryostat, thereby cooling the gas to the temperature of the frozen ice block. This prevents melting of the tissue block that would occur if the gas were at room temperature.
  • Fiducial Placement Precise positioning of fiducial markers in a tissue block can be a difficult and time-consuming procedure.
  • Fiducial markers are critical for FHT applications because they permit orientation of each slice relative to the original block, and permit correction for geometric and color aberrations during slicing and imaging. In some embodiments, they also permit calculation of the point-spread function, which is required to correct for the attenuation of light due to absorption and scattering, and thus reconstruction of the proper fluorescence image.
  • apparatus 1500 for precisely placing fiducial markers in a tissue block is shown, according to various embodiments.
  • apparatus 1500 may be configured to engage a tissue chamber 1504 in which a tissue specimen is retained. Extending through apparatus 1500 may be any number of apertures through which fiducials 1502 may be placed, thereby inserting fiducials 1502 into the tissue specimen.
  • Apparatus 1500 may be formed of any suitable material such as ABS plastic or the like.
  • Damage to the cutting blade of the histological slicing instrument may also be
  • FIG. 16 an example of multi-colored fiducial markers 1502 is shown.
  • the fiducial markers 1502 may be dipped in a solution of chemical or paint to mark one end with a color different from the original color.
  • a color different from the original color For example, if fiducial 1502a is gray in color, the distal 1-2 mm might be colored black. Or, if fiducial 1502b is black, such is the case with squid ink-infused pasta, the distal 1-2 mm might be painted or bleached to a gray or white color.
  • the fiducial 1502 is placed onto the specimen retainer 110 such that the end closest to the block support has the alternate color of a specified length ("the unsafe zone").
  • custom imaging software may continuously identify both the position and color of the fiducial 1502. When the color changes from the primary color to the alternate color, the software will stop all slicing, thus preventing damage to the blade.
  • the colors throughout the vertical height of the fiducial could be selected so that the exact depth of each slice could be estimated. For example, if a 5 mm fiducial changed color every mm from red, to orange, to blue, to green, to yellow, the depth of cutting could be estimated by imaging the transition from one color to another and interpolating based on a known tissue slice depth.
  • the techniques herein therefore, provide for the mounting of a FHT imaging system within the chamber of a cryomicrotome, to perform FHT imaging on the block face of a tissue specimen within the chamber.
  • the imaging components of the system may be located within a transportable housing, thereby protecting the components from the conditions within the chamber and allowing a user to install, position, and remove the imaging components from the cryomicrotome as desired.
  • the FHT system herein can be easily adapted for use with any number of existing cryomicrotomes without significant modification.
  • the methods according to the inventive concepts may be embodied as a non-transitory computer program product. Any combination of one or more computer readable storage device(s) or computer readable media may be utilized.
  • the computer readable medium may be a computer readable storage medium.
  • a computer readable storage device may be, for example, but not limited to, an electronic, magnetic, optical, electromagnetic, or semiconductor system, apparatus, or device, or any suitable combination of the foregoing.
  • a computer readable storage device may be any tangible device or medium that can store a program for use by or in connection with an instruction execution system, apparatus, or device.
  • the term "computer readable storage device,” or variations thereof, does not encompass a signal propagation media such as a copper cable, optical fiber or wireless transmission media.
  • Program code embodied on a computer readable storage device or computer readable medium may be transmitted using any appropriate medium, including but not limited to wireless, wireline, optical fiber cable, RF, etc., or any suitable combination of the foregoing.
  • Computer program code for carrying out operations for aspects of the present invention may be written in any combination of one or more programming languages, including an object oriented programming language such as Java, Smalltalk, C++ or the like and conventional procedural programming languages, such as the "C" programming language or similar programming languages.
  • the program code may execute entirely on the user's computer, partly on the user's computer, as a stand-alone software package, partly on the user's computer and partly on a remote computer or entirely on the remote computer or server.
  • the remote computer may be connected to the user's computer through any type of network, including a local area network (LAN) or a wide area network (WAN), or the connection may be made to an external computer (for example, through the Internet using an Internet Service Provider).
  • LAN local area network
  • WAN wide area network
  • Internet Service Provider an Internet Service Provider
  • These computer program instructions may also be stored in one or more computer readable storage devices or computer readable media that can direct one or more computers, one or more other programmable data processing apparatuses, or one or more other devices to function in a particular manner, such that the instructions stored in the one or more computer readable storage devices or computer readable medium produce an article of manufacture including instructions which implement the function/act specified in the flowchart and/or block diagram block or blocks.
  • the computer program instructions may also be loaded onto one or more computers, one or more other programmable data processing apparatuses, or one or more other devices to cause a series of operational steps to be performed on the one or more computers, one or more other programmable data processing apparatuses, or one or more other devices to produce a computer implemented process such that the instructions which execute on the one or more computers, one or more other programmable data processing apparatuses, or one or more other devices provide processes for implementing the functions/acts specified in the flowchart and/or block diagram block or blocks.

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Pathology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Investigating, Analyzing Materials By Fluorescence Or Luminescence (AREA)
  • Sampling And Sample Adjustment (AREA)

Abstract

Dans un mode de réalisation, l'invention concerne un système d'histo-tomographie de fluorescence (FHT). Le système FHT comprend un boîtier, une caméra de fluorescence située à l'intérieur du boîtier, une caméra à lumière blanche située à l'intérieur du boîtier, et une source de lumière de fluorescence située à l'intérieur du boîtier. Le système FHT comprend en outre une monture de support configurée pour porter le boîtier à l'intérieur d'une chambre d'un appareil de tranchage, de telle sorte que les caméras et la source de lumière de fluorescence sont dirigées vers une face de bloc d'un échantillon de tissu retenu à l'intérieur de la chambre.
PCT/US2016/049708 2015-08-31 2016-08-31 Systèmes et procédés d'histo-tomographie de fluorescence (fht) WO2017040671A1 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
KR1020187002483A KR20180048586A (ko) 2015-08-31 2016-08-31 형광 조직-단층촬영(fht) 시스템 및 방법
AU2016315795A AU2016315795C1 (en) 2015-08-31 2016-08-31 Fluorescence histo-tomography (FHT) systems and methods
EP16842910.8A EP3298383A4 (fr) 2015-08-31 2016-08-31 Systèmes et procédés d'histo-tomographie de fluorescence (fht)
CA2987919A CA2987919A1 (fr) 2015-08-31 2016-08-31 Systemes et procedes d'histo-tomographie de fluorescence (fht)
JP2018530666A JP6719123B2 (ja) 2015-08-31 2016-08-31 蛍光組織断層撮影（ｆｈｔ）システムおよびｆｈｔ方法

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562211930P 2015-08-31 2015-08-31
US62/211,930 2015-08-31
US15/158,928 US9799113B2 (en) 2015-05-21 2016-05-19 Multi-spectral three dimensional imaging system and method
US15/158,928 2016-05-19

Publications (1)

Publication Number Publication Date
WO2017040671A1 true WO2017040671A1 (fr) 2017-03-09

Family

ID=58188254

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/049708 WO2017040671A1 (fr) 2015-08-31 2016-08-31 Systèmes et procédés d'histo-tomographie de fluorescence (fht)

Country Status (6)

Country Link
EP (1) EP3298383A4 (fr)
JP (2) JP6719123B2 (fr)
KR (1) KR20180048586A (fr)
AU (1) AU2016315795C1 (fr)
CA (1) CA2987919A1 (fr)
WO (1) WO2017040671A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018175227A1 (fr) * 2017-03-24 2018-09-27 Curadel, LLC Identification de tissu par un système d'imagerie utilisant des informations de couleur
EP3964817A1 (fr) 2020-09-03 2022-03-09 Inpeco SA Dispositif et procédé pour l'insertion automatique d'un matériau de référence pendant le traitement d'un échantillon biologique
EP3801191A4 (fr) * 2018-06-07 2022-03-30 Curadel, LLC Approche de masquage pour l'imagerie de fluorophores multi-pics par un système d'imagerie

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102304036B1 (ko) * 2019-11-27 2021-09-17 울산과학기술원 연속 블록면 광간섭 현미경 장치
EP4105707A4 (fr) * 2020-03-19 2023-08-23 Sony Olympus Medical Solutions Inc. Système d'observation médicale, dispositif de commande et procédé de commande
US20220020481A1 (en) 2020-07-20 2022-01-20 Abbott Laboratories Digital pass verification systems and methods

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050253087A1 (en) * 2001-08-09 2005-11-17 Thomas Plan Fluorescence diagnostic system
US20070083124A1 (en) * 2005-09-26 2007-04-12 Thomas Ehben Method and apparatus for displaying a tissue containing a fluorescent dye
US20090236541A1 (en) * 2008-03-24 2009-09-24 General Electric Company System and Methods for Optical Imaging
US20110091088A1 (en) * 2005-10-20 2011-04-21 Wilson David L Imaging system
US20110152714A1 (en) * 2009-06-23 2011-06-23 Luginbuhl Christopher Variable angle guide holder for a biopsy guide plug
US20140248210A1 (en) * 2009-07-02 2014-09-04 Cornell University Multimodal silica-based nanoparticles

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH10123054A (ja) * 1996-10-23 1998-05-15 Kagaku Gijutsu Shinko Jigyodan 試料観察方法及びその装置
JP2006010620A (ja) * 2004-06-29 2006-01-12 Canon Inc 顕微鏡観察用断面試料の作成方法、およびウルトラミクロトーム
US7507575B2 (en) * 2005-04-01 2009-03-24 3M Innovative Properties Company Multiplex fluorescence detection device having removable optical modules
KR100853655B1 (ko) * 2006-12-15 2008-08-25 한국전기연구원 피부 질환의 광학 진단 및 치료를 위한 장치, 광원 시스템 및 장치의 이용방법
WO2010042217A1 (fr) * 2008-10-09 2010-04-15 Sti Medical Systems, Llc Procédé de maintien d’une orientation tridimensionnelle afin de permettre l'enregistrement de diagnostics histopathologiques de tissus
JP5564654B2 (ja) * 2010-05-31 2014-07-30 岩崎電気株式会社 Ｌｅｄ照射装置
US20140135601A1 (en) * 2012-11-09 2014-05-15 Kestrel Labs, Inc. User replaceable optical subsystem for laser-based photoplethysmography
CN105263390A (zh) * 2013-04-23 2016-01-20 雪松-西奈医学中心 用于从荧光团同时录制可见光图像和红外光图像的系统和方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20050253087A1 (en) * 2001-08-09 2005-11-17 Thomas Plan Fluorescence diagnostic system
US20070083124A1 (en) * 2005-09-26 2007-04-12 Thomas Ehben Method and apparatus for displaying a tissue containing a fluorescent dye
US20110091088A1 (en) * 2005-10-20 2011-04-21 Wilson David L Imaging system
US20090236541A1 (en) * 2008-03-24 2009-09-24 General Electric Company System and Methods for Optical Imaging
US20110152714A1 (en) * 2009-06-23 2011-06-23 Luginbuhl Christopher Variable angle guide holder for a biopsy guide plug
US20140248210A1 (en) * 2009-07-02 2014-09-04 Cornell University Multimodal silica-based nanoparticles

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
DELAQUIS ET AL.: "Development of a camera casing suited for cryogenic and vacuum applications.", ARXIV, 24 October 2013 (2013-10-24), pages 1 - 11, XP020254917, Retrieved from the Internet <URL:https://arxiv.org/pdf/1310.6601v1.pdf> *
See also references of EP3298383A4
SHEN ET AL.: "Automated Fluorescence and Reflectance Coregistered 3-D Tissue Imaging System.", IEEE TRANSACTIONS ON MAGNETICS, vol. 49, no. 1, January 2013 (2013-01-01), pages 279 - 283, XP011483129, Retrieved from the Internet <URL:http://www.controlofmems.umd.edu/publications/journal-papers/2013/ShenEtAl-3DCrystat-Imaging-Jan2013.pdf> *
Z. SHEN ET AL.: "Automated Fluorescence and Reflectance Coregistered 3-D Tissue Imaging System", IEEE TRANSACTIONS ON MAGNETICS, vol. 49, 2013, pages 279 - 284, XP011483129, DOI: doi:10.1109/TMAG.2012.2222360

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018175227A1 (fr) * 2017-03-24 2018-09-27 Curadel, LLC Identification de tissu par un système d'imagerie utilisant des informations de couleur
US10580130B2 (en) 2017-03-24 2020-03-03 Curadel, LLC Tissue identification by an imaging system using color information
EP3801191A4 (fr) * 2018-06-07 2022-03-30 Curadel, LLC Approche de masquage pour l'imagerie de fluorophores multi-pics par un système d'imagerie
EP3964817A1 (fr) 2020-09-03 2022-03-09 Inpeco SA Dispositif et procédé pour l'insertion automatique d'un matériau de référence pendant le traitement d'un échantillon biologique

Also Published As

Publication number Publication date
JP2020169999A (ja) 2020-10-15
AU2016315795A1 (en) 2017-12-14
JP6719123B2 (ja) 2020-07-08
JP7093086B2 (ja) 2022-06-29
CA2987919A1 (fr) 2017-03-09
AU2016315795C1 (en) 2022-03-10
EP3298383A4 (fr) 2019-01-16
EP3298383A1 (fr) 2018-03-28
JP2018534584A (ja) 2018-11-22
KR20180048586A (ko) 2018-05-10
AU2016315795B2 (en) 2021-09-09

Similar Documents

Publication Publication Date Title
US11385222B2 (en) Fluorescence histo-tomography (FHT) systems and methods
AU2016315795B2 (en) Fluorescence histo-tomography (FHT) systems and methods
EP3194937B1 (fr) Procédé pour commander la profondeur d&#39;imagerie dans des tissus à l&#39;aide de microscopie par fluorescence sous excitation aux ultraviolets après coloration avec des agent fluorescents
US9964489B2 (en) System and method for controlling depth of imaging in tissues using fluorescence microscopy under ultraviolet excitation following staining with fluorescing agents
Hübner et al. Standardized quantification of pulmonary fibrosis in histological samples
JP2011530082A (ja) 細胞ミクロ構造の共焦点画像化のための染料適用
EP3298588B1 (fr) Système et procédé d&#39;imagerie tridimensionnelle multi-spectrale
WO2018175565A1 (fr) Système et procédé pour commander la profondeur d&#39;imagerie dans les tissus à l&#39;aide de la microscopie de fluorescence sous excitation aux ultraviolets après coloration avec des agents fluorescents
WO2012112911A2 (fr) Dispositifs et méthodes pour une pathologie optique
KR20200083512A (ko) 수술 중의 외과적 마진 평가를 위한 이미징 방법 및 시스템
WO2019209743A1 (fr) Imagerie tridimensionnelle de tissu de grade histologique à l&#39;aide d&#39;un microscope à excitation de surface ultraviolette
US20120251452A1 (en) Apparatus and method for identifying one or more amyloid beta plaques in a plurality of discrete oct retinal layers
Bhattacharjee et al. Label-free imaging and optical characterization of tissues based on autofluorescence
Atwood et al. Quantitation of microcomputed tomography‐imaged ocular microvasculature
Sarantopoulos et al. Imaging the bio-distribution of molecular probes using multispectral cryoslicing imaging
Roblyer et al. Optical diagnostics for early detection of oral cancer
Linssen Fluorescently labelled monoclonal antibodies for real-time molecular imaging: pharmaceutical development of near-infrared tracers and their application in clinical settings
Rosbach et al. Quantitative Image Analysis to Predict the Neoplastic Region in Oral Squamous Cell Carcinoma using Multiple Fluorescent Contrast Agents
Phd et al. Circ Cardiovasc Imaging. 2010 Sep; 3 (5): 567-77 el Kaijzel1 Phd, PM van heijningen2 Msc, PA Wielopolski3 Phd, M. Vermeij4 Msc, GA Koning5 Phd, WA van Cappellen6 Phd, i. Que1 Msc, A. Chan7 Phd, J. dijkstra8 Phd, NWM Ramnath2, 9 Msc, lJAC hawinkels10

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16842910

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 2987919

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2016315795

Country of ref document: AU

Date of ref document: 20160831

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 20187002483

Country of ref document: KR

Kind code of ref document: A

ENP Entry into the national phase

Ref document number: 2018530666

Country of ref document: JP

Kind code of ref document: A

NENP Non-entry into the national phase

Ref country code: DE